×
About 9,000 results

ALLMedicine™ Myelofibrosis Center

Research & Reviews  4,245 results

Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis o...
https://doi.org/10.1111/ijlh.13560
International Journal of Laboratory Hematology; Zheng CF, Zhao XX et. al.

May 11th, 2021 - This study developed a method for quantifying the JAK2V617F mutation load in patients with myeloproliferative neoplasm (MPN) using droplet digital PCR (ddPCR), which provides a new laboratory method for diagnosing polycythemia vera (PV), essential...

Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
https://doi.org/10.1093/ajcp/aqab027
American Journal of Clinical Pathology; Goyal T, Tu ZJ et. al.

Apr 30th, 2021 - This study seeks to further characterize the clinicopathologic spectrum of DDX41-mutated hematolymphoid malignancies. We identified DDX41 mutations from a cohort of known or suspected hematologic disorders and reviewed the corresponding clinical, ...

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: ...
https://doi.org/10.3390/curroncol28020146
Current Oncology (Toronto, Ont.); Varghese C, Immanuel T et. al.

Apr 30th, 2021 - There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). This st...

Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085640
International Journal of Hematology; Kawabata H, Fujimoto S et. al.

Apr 30th, 2021 - To identify prognostic factors for TAFRO syndrome, a rare inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Data of patients with TAFRO syndr...

see more →

Guidelines  17 results

A physician survey on the application of the British Society for Haematology guidelines...
https://doi.org/10.1111/bjh.16390
British Journal of Haematology; Harrison CN, Mead AJ et. al.

Feb 22nd, 2020 - A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK.|2020|Harrison CN,Mead AJ,Drummond MW,Chiu G,Bains R,|diagnosis,therapy,

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 6th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
http://www.jnccn.org/content/15/10/1193.full
Mesa, R.,et al

Sep 30th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh.

see more →

Drugs  7 results see all →

Clinicaltrials.gov  4,465 results

Quantification of JAK2V617F mutation load by droplet digital PCR can aid in diagnosis o...
https://doi.org/10.1111/ijlh.13560
International Journal of Laboratory Hematology; Zheng CF, Zhao XX et. al.

May 11th, 2021 - This study developed a method for quantifying the JAK2V617F mutation load in patients with myeloproliferative neoplasm (MPN) using droplet digital PCR (ddPCR), which provides a new laboratory method for diagnosing polycythemia vera (PV), essential...

Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
https://doi.org/10.1093/ajcp/aqab027
American Journal of Clinical Pathology; Goyal T, Tu ZJ et. al.

Apr 30th, 2021 - This study seeks to further characterize the clinicopathologic spectrum of DDX41-mutated hematolymphoid malignancies. We identified DDX41 mutations from a cohort of known or suspected hematologic disorders and reviewed the corresponding clinical, ...

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: ...
https://doi.org/10.3390/curroncol28020146
Current Oncology (Toronto, Ont.); Varghese C, Immanuel T et. al.

Apr 30th, 2021 - There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF). This st...

Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085640
International Journal of Hematology; Kawabata H, Fujimoto S et. al.

Apr 30th, 2021 - To identify prognostic factors for TAFRO syndrome, a rare inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Data of patients with TAFRO syndr...

see more →

News  255 results

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_2

Jul 15th, 2020 - Figure 1. Enlarged spleen (splenomegaly). Light micrograph of a section through an enlarged spleen that has occurred in myelofibrosis. PMF is an uncommon disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in t...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_1

Jul 15th, 2020 - Formerly known as "agnogenic myeloid metaplasia," primary myelofibrosis (PMF) is a bone marrow and blood cancer in which a clonal disorder arises from the neoplastic transformation of early hematopoietic stem cells. One of a heterogeneous group of...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699

Jul 15th, 2020 - Formerly known as "agnogenic myeloid metaplasia," primary myelofibrosis (PMF) is a bone marrow and blood cancer in which a clonal disorder arises from the neoplastic transformation of early hematopoietic stem cells. One of a heterogeneous group of...

Fast Five Quiz: Prognosis of Primary Myelofibrosis
https://reference.medscape.com/viewarticle/933699_4

Jul 15th, 2020 - A Mayo-Careggi MPN Alliance study found that among 709 Mayo Clinic patients with PMF, 66% had a JAK2 mutation, 19% had a CALR mutation, and 5.4% had an MPL mutation. A further 10% of patients were triple-negative for these mutations. Patients with...

see more →

Patient Education  11 results see all →